ACM
EW icon

Avalon Capital Management’s Edwards Lifesciences EW Stock Holding History

Avalon Capital Management’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-4,479
Closed -$332K – 136
2024
Q4 		$332K Sell
4,479
-235
-5% -$16.4K 0.11% 100
2024
Q3 		$311K Sell
4,714
-498
-10% -$36.2K 0.09% 105
2024
Q2 		$481K Buy
+5,212
New +$462K 0.15% 75

Other funds holding EW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Avalon Capital Management's EW Position: Q1 2025 in Review

Avalon Capital Management sold out of Edwards Lifesciences (EW) in Q1 2025, closing a stake of 4,479 shares — an estimated $332K sold.

Avalon Capital Management first reported a position in EW in Q2 2024 and held it in 3 quarters. The position peaked at $481K in Q2 2024. 1,206 funds tracked by Wall St. Rank hold EW as of Q1 2025.

  • Avalon Capital Management reported no remaining Edwards Lifesciences position as of Q1 2025 after selling out during the quarter.
  • Avalon Capital Management sold 4,479 Edwards Lifesciences shares in Q1 2025, an estimated $332K.
  • Avalon Capital Management first reported a position in Edwards Lifesciences in Q2 2024 and held it in 3 quarters.
  • Avalon Capital Management's Edwards Lifesciences position peaked at $481K in Q2 2024.
  • 1,206 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2025.

Based on Avalon Capital Management's 13F filing for Q1 2025, filed 7 May 2025.